Minodronic acid API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Minodronic acid is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Minodronic acid or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Minodronic acid API 180064-38-4?

Description:
Here you will find a list of producers, manufacturers and distributors of Minodronic acid. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Minodronic acid 
Synonyms:
Minodronate , Minodronic acid  
Cas Number:
180064-38-4 
DrugBank number:
DB06548 
Unique Ingredient Identifier:
40SGR63TGL

General Description:

Minodronic acid is a chemical compound identified by the CAS number 180064-38-4. It is known for its distinct pharmacological properties and applications.

Indications:

This drug is primarily indicated for: Investigated for use/treatment in multiple myeloma, breast cancer, osteoporosis, and lung cancer. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Classification:

Minodronic acid belongs to the class of organic compounds known as imidazopyridines. These are organic polycyclic compounds containing an imidazole ring fused to a pyridine ring. Imidazole is 5-membered ring consisting of three carbon atoms, and two nitrogen centers at the 1- and 3-positions. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center, classified under the direct parent group Imidazopyridines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Imidazopyridines class, specifically within the None subclass.

Categories:

Minodronic acid is categorized under the following therapeutic classes: Organophosphonates, Organophosphorus Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Minodronic acid is a type of Anticancer drugs


Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.

Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.

These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.

Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.